MicroRNAs (miRNAs) constitute a class of small cellular RNAs (typically 21-23 nt) that function as posttranscriptional regulators of gene expression. Current estimates indicate that more than one third of the cellular transcriptome is regulated by miRNAs, although they are relatively few in number (less than 2000 human miRNAs).
Introduction
microRNAs (miRNAs) constitute a class of small RNAs that function as post-transcriptional regulators of gene expression [1] . Although they are relatively few in number (<2000 human miRNAs), current estimates indicate that more than one third of the cellular transcriptome is regulated by miRNAs [2] . Unsurprisingly therefore, miRNAs play important regulatory roles in most cellular and developmental processes and have been implicated in a large number of human diseases [3, 4] . Since the discovery of extracellular and circulating microRNAs a few years ago, the study of microRNAs in biofluids such as serum, plasma, urine and cerebrospinal fluid has rapidly expanded [5] . Due to their wide-ranging biological potential and the fact that miRNAs seem to be relatively stable in readily available biofluids, these small 21-23 nt molecules are prime candidates for use as non-invasive biomarkers in molecular diagnostics of disease and other clinical conditions such as organ damage as well as pre-clinical toxicology and drug safety assessments [6] . Indeed numerous studies have shown that secreted microRNAs can be implicated in pathogenic conditions such as various cancers, coronary heart disease and organ damage [7] [8] [9] [10] .
The precise role of circulating miRNAs is still largely unknown. Circulating or extracellular miRNAs have been shown to be stabilized and protected from RNAse degradation by inclusion in various protein complexes or membranous particles such as exosomes or microvesicles [11] [12] [13] [14] . There does seem to be a subset of cell-free microRNAs present in normal blood with possible functions within the circulatory and immune systems [15] . The miRNA profile in serum and plasma has been shown to reflect disease states such as cancer [16] as well as organ damage and injury [17] . It has also been shown that miRNA containing subcellular vesicles can be taken up by cells and cause changes in cellular gene expression during pathological conditions [18, 19] . These findings suggest a biological function for extra-cellular miRNA yet to be fully described.
From the analytical viewpoint miRNAs in serum and plasma have been shown to be stable for up to 48 h even when stored at room temperature and are also stable after multiple freeze-thaw cycles (in house data). However the accurate and robust measurement of miRNAs in biofluids is made challenging by a number of factors. Firstly the miRNAs themselves are very short and consist of highly divergent sequences with large variation in GC content. This variability leads to very different hybridization properties between different miRNA sequences and makes simultaneous measurement of all miRNAs challenging. Although miRNAs are highly divergent in general, individual members of miRNA families are highly similar, sometimes varying only by a single nucleotide. Secondly, the overall amount of miRNA, and RNA in general, that is present in samples such as serum and plasma is very low. Reproducible and robust isolation of miRNAs from serum and plasma can be achieved by the addition of carrier RNA during the isolation procedure [20] . The use of a highly sensitive, specific and accurate miRNA qPCR method that allows linear detection of miRNAs even at very low target concentrations is also essential. Both of these challenges can be overcome by the use of short LNA™-enhanced, microRNA specific primers for detection of reverse transcribed miRNAs [21] .
To move microRNA discovery from the molecular biology lab to the clinic requires not only a highly reliable and reproducible assay system, but also requires that pre-analytical and analytical variables are easily identified and accounted for by thorough quality control of the samples being analyzed. Sampling, and sample preparation as well as RNA isolation and storage can be sources of pre-analytical variation. A number of recent papers have discussed various pre-analytical variables for miRNA profiling in serum and/or plasma [22] [23] [24] . These studies have shown that cellular contamination and hemolysis of plasma (and serum) samples can be a major cause of variation in miRNA levels not related to any biological difference. A common source of analytical variation is the co-purification of qPCR inhibitors known to be present in serum and plasma in the RNA sample itself.
We have developed a highly sensitive and accurate miRNA qPCR system which has been shown to be especially well suited to the analysis of biofluid samples with limited RNA content, such as serum and plasma [25] . The miRNA assays are all (95%) validated to be linear down to 10 copies of microRNA target in the PCR reaction (equivalent to 4000 copies in a 20 ll cDNA synthesis reaction) which is essential for achieving accurate miRNA measurements without the potential biases which can be introduced by preamplification.
Using this system we have profiled miRNA from over 1500 serum and plasma samples. The samples used have come from a large number of different sources and have therefore been subjected to extensive quality control measures both before RNA isolation and on the RNA itself in order to remove any bias which could be linked to e.g. sampling methods, storage or purification. Successful biomarker discovery projects are dependent on controlling for these sources of pre-analytical variation. As a result we have developed a normal reference range for 119 miRNAs in serum and plasma as well as an RNA QC panel consisting of assays for both endogenous miRNAs and spiked-in RNAs for a complete QC of RNA samples. In addition we have developed a hemolysis indicator based on two endogenous microRNAs for use with RNA samples or archival data.
Material and methods

RNA isolation
Total RNA was extracted from serum using a commercial column-based system following the manufacturer's instructions with the following modifications (Qiagen miRNeasy Ò Mini Kit). water to the membrane of the spin column and incubating for 1 min before centrifugation at 15,000Âg for 1 min at room temperature. The RNA was stored at À80°C.
RNA spike-in
The RNA spike-in kit (Exiqon A/S) was used according to the manufacturer's instructions.
cDNA synthesis and real time PCR
8 ll of RNA eluate was reverse transcribed in 40 ll reactions using the miRCURY LNA™ Universal RT cDNA Synthesis Kit (Exiqon). The cDNA was diluted 50 x and assayed in 10 ul PCR reactions according to the protocol for the miRCURY LNA™ Universal RT microRNA PCR System (Exiqon A/S); each microRNA was assayed once by qPCR on the Serum/plasma Focus microRNA PCR panel. A no-template control (NTC) of water was purified with the samples and profiled like the samples. The amplification was performed in a LightCycler Ò 480 Real-Time PCR System (Roche) in 384 well plates. The amplification curves were analyzed using the Roche LC software, both for determination of Cp (by the second derivative method) and for melting curve analysis.
Data filtering and analysis
The amplification efficiency was calculated using algorithms similar to the LinReg software [26, 27] . All assays were inspected for distinct melting curves and the Tm was checked to be within known specifications for each particular assay. Furthermore any sample assay data point must be detected with 5 Cps less than the corresponding negative control assay data point, and with a Cp < 37 to be included in the data analysis. Data that did not pass these criteria were omitted from any further analysis.
Results and discussion
Establishing a normal reference range of miRNA expression in serum and plasma
Recent reports have suggested that a common source of unwanted bias in miRNA profiles in serum and plasma samples is cellular contamination of the samples with various blood cell types [22] . It is vital for any biomarker discovery project utilizing cell free microRNA from serum or plasma that the cellular content of the biofluid is minimized, that miRNA expression levels are interpreted in light of blood cell counts, or that miRNA biomarkers are sought among miRNAs that are not expressed in blood cells. Minimizing cellular content can be done by standardizing the sampling procedure as well as the handling of the material. The National Cancer Institute Early Detection Research Network (EDRN) has recently published standard operating protocols for the sampling procedure including serum and plasma [28] . After sampling it is important to treat the biofluids according to instructions of the sampling tube manufacturer. Separation of the red blood cells, buffy coat and the plasma must be done carefully to not disturb the buffy coat. After collection of plasma we recommend spinning once again to minimize buffy coat contamination.
For serum this step is not necessary due to the coagulation of the sample.
The presence of small amounts of cellular contamination in serum or plasma samples is not readily detectable by visual or spectrophotometric means. The effect on the miRNA expression profile in the resulting RNA samples depends on the amount of cellular carry over and the precise cell types and will therefore be wide ranging. In order to identify samples with potential cellular contamination, we identified the 119 microRNAs that are most commonly present in serum and plasma samples (see material and methods for details of data QC and filtering, see appendix for the list of microRNAs). The results of microRNA profiling on 381 samples that passed standard quality control were used to generate a mean qualification cycle value for each of the 119 microRNAs. Fig. 1A shows the mean Cq values for this normal reference range of miRNA expression in serum/plasma using the miRCURY LNA™ microRNA PCR system as well as a representative sample which was known to be of high quality and free from cellular contamination. It is clear that although the representative plasma sample varies from the mean values, the overall miRNA expression levels are similar.
In order to be able to identify outlier samples as well as to control for cellular contamination, we generally compare all miRNA profiles obtained from serum and plasma with the reference range values. Fig. 1A also shows an example of a compromised plasma sample that is probably contaminated with blood cells. The overall miRNA levels in the sample are clearly different from the mean values. The comparison in Fig. 1A is done before normalization, but normalizing the miRNA profiling data using a geometric mean of all values does not rescue the compromised sample from being recognized as being significantly different from the reference sample (Fig. 1B-C) . When comparing miRNA profiles from serum or plasma samples it is important that the samples are as technically similar as possible in order to optimally detect the biological variation of interest. Samples with very different miRNA expression profiles from the rest of the samples in the project should not be included in the final data analysis.
Controlling hemolysis in RNA samples and archival data
Another recently reported source of significant variation in miR-NA profiles from serum/plasma is hemolysis (rupturing of erythrocytes) [21] . Hemolysis can occur in most steps of the sampling and handling procedures until serum/plasma has been separated from the rest of the circulatory components. Monitoring hemolysis in serum and plasma samples can however be done by various methods that measure free hemoglobin levels. A simple and cost effective way is to use a spectrophotometer and measure oxyhemoglobin absorbance at k = 414 nm. Distinct absorbance peaks can be used to disqualify hemolysis samples before time consuming and costly downstream sample processing takes place. An example of spectrophotometric analysis of representative serum and plasma samples affected by hemolysis is shown in Fig. 2A .
However, if the original serum or plasma sample is no longer available and only purified RNA is available, an alternative method to identify putative hemolyzed samples is to use miRNAs known to be enriched in erythrocytes like miR-451 or miR-144 [29] . As the level of these miRNAs can also be influenced by other factors such as pre-clinical variables, disease state, tissue/organ damage and natural variation, a simple threshold cannot be used as an indicator of hemolysis. The level of the erythrocyte specific miRNA must be related to a miRNA found to be un-affected by hemolysis and this will allow identification and, if required, elimination of outlier samples.
In our experience miR-23a is relatively stable in plasma and serum and is not affected by hemolysis. We have found that a delta Cq (miR-23a-miR-451) of more than five is an indicator of possible erythrocyte miRNA contamination, and a delta Cq of 7-8 or more indicates a high risk of hemolysis affecting the data obtained (Fig. 2B) . In our quality control process for serum and plasma samples, we use this hemolysis indicator to (1) monitor sampling protocols and sampling sites (2) disqualify outliers (e.g. samples with highly different delta Cq (miR-23a-miR-451) values) and (3) monitor that hemolysis is not affecting specific sample groups being interrogated. This hemolysis indicator can also easily be applied to archival data.
It is important to note that many miRNAs in serum and plasma are not affected by hemolysis and therefore it may still be possible to detect disease associated miRNA biomarkers even from samples affected by hemolysis. However it is crucial to be aware of the possible effects on the miRNA profile when performing normalization and data analysis so that any systematic bias can be eliminated. We have shown that applying a pre-set cut-off for indications of hemolysis on a dataset from clinical plasma samples could improve the sensitivity and specificity of a miRNA signature for early colorectal cancer significantly ( [30] and unpublished data).
A qPCR based RNA QC method
A third source of possible variation in miRNA profiles from serum and plasma is the RNA isolation procedure and specifically the presence of inhibitors that affect the cDNA synthesis and/or realtime PCR reactions. As cell-free miRNA concentrations are low in these samples, it is tempting to try to maximize the amount of sample used per reaction. However, increasing the amount of RNA input could also lead to an increased concentration of inhibitors which may be derived from the biofluid or introduced via reagent carry-over during sample preparation and suboptimal RNA isolations. Variation in RNA isolation efficiency is difficult to identify as the yield of RNA from serum and plasma is very low and robust RNA purification therefore requires the addition of carrier. This means that the amount of miRNA in the samples cannot be accurately measured and used to determine input amounts.
In order to control for sample specific effects on assay performance we have developed a set of synthetic oligonucleotides that share common sequence features with miRNAs (short length and variable GC content from 43-50%). A subset of these synthetic RNA templates can be spiked into the serum or plasma samples during the RNA isolation procedure via the lysis buffer in three different concentrations. This subset of spike-ins is used to measure and compare the yield from different RNA extractions. A second RNA spike-in is used to monitor the efficiency of the cDNA synthesis reaction for signs of inhibitors and a third DNA spike-in is used to monitor the real-time PCR reaction. A no-template control (NTC), that is a water sample that has been taken through the RNA isolation process like the other samples including the addition of spike-ins, is also recommended. The NTC is then profiled to monitor the baseline for the spike-ins and can be used to reveal potential inhibitions. Fig. 3 shows an example of results from the set of RNA and DNA spike-ins on two plasma samples.
The use of a set of spike-in templates during RNA isolation combined with a carefully selected set of assays targeting endogenous miRNAs can be used as a qPCR-based quality control procedure for RNA samples from biofluids including serum and plasma. The spike-in templates are used to monitor yield and possible contamination by inhibitors. Expression patterns of endogenous miRNAs can be used to identify putative outliers and samples affected by hemolysis or inhibition. An up-front quality control of RNA from serum and plasma using a small panel of assays can thereby be used to monitor important sources of pre-analytical and analytical variables and ensure high quality data from the subsequent miRNA profiling study.
Conclusions
miRNAs present in biofluids such as plasma and serum show great promise as minimally invasive biomarkers for diverse pathological conditions. Although they have great promise, miRNAs in biofluids are very challenging to measure accurately and preanalytical and technical factors can easily affect the miRNA levels resulting in biases that do not reflect the biological state of the samples. We have described a versatile LNA™-based qPCR method for genome-wide profiling of miRNAs with absolute sensitivity, accuracy and ease-of-use that is optimal for measuring miRNAs in biofluids and other clinical samples.
We have strengthened this PCR system with an extensive QC and data analysis pipeline that has been developed and implemented in order to facilitate biomarker discovery and assay development studies by identifying and eliminating pre-analytical and technical factors in samples. By monitoring the Cq profile of the 119 miRNAs most commonly expressed in serum and plasma, we can quickly identify samples affected by sources of pre-analytical variation such as cellular contamination. The relative expression of the erythrocyte specific miR-451 and the stable miR-23a can be used as an indicator of hemolysis in RNA samples or miRNA profiling data from serum and plasma samples. Finally, a minimal set of qPCR assays for synthetic and endogenous targets can be used as a qPCR based method for quality control of RNA samples isolated from biofluids.
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